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Hepatitis  C  virus  (HCV)  is  a public  health  problem  throughout  the  world  and  3%  of the  world  population
is  infected  with  this  virus.  It is  estimated  that  3–4 millions  individuals  are  being  infected  every year.
It  has  been  estimated  that  around  1.5% of  Brazilian  population  is  anti-HCV  positive  and  the  Northeast
region  showed  the  highest  prevalence  in  Brazil.  The aim  of this  study  was to  characterize  HCV  geno-
types  circulating  in  Pernambuco  State  (PE),  Brazil,  located  in  the  Northeast  region  of  the  country.  This
study  included  85  anti-HCV  positive  patients  followed  up  between  2004  and  2011.  For  genotyping,  a
380bp  fragment  of  HCV  RNA  in  the  NS5B  region  was  ampliﬁed  by  nested  PCR.  Phylogenetic  analysis  was
conducted  using  Bayesian  Markov  chain  Monte  Carlo  simulation  (MCMC)  using  BEAST  v.1.5.3.  From  85
samples,  63  (74.1%)  positive  to NS5B  fragment  were  successfully  sequenced.  Subtype  1b  was  the  mosthylogenetic analysis
S5B  region
prevalent  in  this  population  (42–66.7%),  followed  by  3a  (16–25.4%),  1a (4–6.3%)  and  2b  (1–1.6%).  Twelve
(63.1%)  and  seven  (36.9%)  patients  with  HCV  and  schistosomiasis  were  infected  with  subtypes  1b and  3a,
respectively.  Brazil  is  a  large  country  with  many  different  population  backgrounds;  a large  variation  in the
frequencies  of  HCV  genotypes  is  predictable  throughout  its  territory.  This  study  reports  HCV  genotypes
from  Pernambuco  State  where  subtype  1b  was  found  to be  the  most  prevalent.  Phylogenetic  analysis
suggests  the  presence  of the  different  HCV  strains  circulating  within  this  population.. Introduction
Hepatitis C virus (HCV) is a blood borne pathogen, recognized as
ne of the major causes of chronic liver disease worldwide (Shepard
t al., 2005). According to the World Health Organization, there are
70 million people infected with HCV, corresponding to 3% of the
orld population (McHutchison and Bacon, 2004). Actually, it is
stablished that HCV infection is globally important and is a severe
ealth problem that requires extensive and active interventions for
he prevention and control. Prospective studies have shown that
0% of cases of acute hepatitis C progress to chronic infection and
0–20% of them develop complications of chronic liver disease such
s liver cirrhosis and/or hepatocellular carcinoma (Kiyosawa et al.,
990; Lavanchy (2011); Zhou et al., 2010).
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MT 2, São Paulo, SP, Brazil. Tel.: +55 11 3061 8218; fax: +55 11 3064 5932.
E-mail  address: monica.viviana@usp.br (M.V. Alvarado-Mora).
168-1702/© 2012 Elsevier B.V.
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Open access under the Elsevier OA license.© 2012 Elsevier B.V. 
Africa and Asia are the regions of the world with the highest
prevalence rates while the low prevalence areas include Australia,
North America and Europe. In Latin America, the prevalence of HCV
is 1.2% (Te and Jensen, 2010). Nevertheless, this prevalence varies
from region to region, from 0.2–0.5% in Chile to 1.7–3.4% in North-
east Brazil (Carrilho and Corrêa, 1998; Soza et al., 2010; Te and
Jensen, 2010;). Thus, it is estimated that there are 6.8–8.9 millions
anti-HCV positive inhabitants in Latin America and HCV prevalence
estimated was  1.5% for the Americas in 2010 (Kershenobich et al.,
2011).
HCV is a positive sense single-strand RNA virus with a genome
size of 9400 bp. It contains a large open reading frame that encodes
a precursor polyprotein of about 3000 amino acids (Suzuki et al.,
2007). The virus is classiﬁed in the genus Hepacivirus of the family
Flaviviridae (Ishii et al., 1999). Phylogenetic analyses of full-length
or partial sequences of HCV strains isolated in various regions of the
world has led to the identiﬁcation of six HCV genotypes (1–6), and
Open access under the Elsevier OA license.a large number of subtypes (WHO, 1999; Simmonds et al., 2005).
HCV genotyping is an essential tool for epidemiological studies
(Cantaloube et al., 2006; Mora et al., 2010). There is a wide geo-
graphical variation considering genotype distribution: genotypes
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fFig. 1. Geographical localizati
, 2 and 3 are more frequent in Europe, North America and Japan;
enotype 4 in Central Africa, Egypt and the Middle East; genotype
 in South Africa; and genotype 6 in Asia. These genotypes differ
y 31–34% in their nucleotide sequence and by around 30% in their
mino acid sequence. Accurate HCV genotyping can be used for
redicting response to anti-viral therapy, as genotypes 1 and 4 are
ore difﬁcult than genotypes 2 and 3 to respond to interferon and
ibavirin (Pawlotsky, 2003).
Pernambuco is a state of Brazil located in the North-
ast region of the country. According to the IBGE, there
ere 8,796,448 people residing in this state (IBGE, 2010).
ulatos (African and Portuguese ancestry) and Mamelucos
Amerindian and Portuguese ancestry) are more common in
he coast of this state and in the small towns, respectively
http://www.ibge.gov.br/estadosat/perﬁl.php?sigla=pe). The aim
f this study was to report the current distribution of HCV geno-
ypes in Pernambuco State, Brazil.
. Materials and methods
.1. Study population
This study was carried out in Pernambuco State including 85
CV positive patients (63 from Recife and 22 from other regions
f Pernambuco) collected between 2004 and 2011 in the Central
aboratory of Clinics Hospital, Federal University of Pernambuco
UFPE), Recife, PE, Brazil (Fig. 1). Blood collection was performed
y venipuncture and serum was obtained and stored at −20 ◦C.
ighty-ﬁve patients were analyzed, 43 males and 42 females, with
ge ranging from 26 to 65 years old. Fifty-eight patients were HCV
onoinfected patients, 25 also presented the hepatosplenic form
f schistosomiasis (HCV/HES) and 2 were HCV/HIV coinfected.
Considering previous treatment, 53 patients were naïve and
2 of them have been previously treated with pegylated inter-
eron (PEG-IFN) and ribavirin (Calvaruso and Craxi, 2012). Fibrosisernambuco state (PE), Brazil.
METAVIR stage indexes were obtained from liver biopsies per-
formed in 51/85 patients: F0 = 3 (5.88%), F1 = 14 (27.4%), F2 = 18
(35.3%), F3 = 12 (23.5%) and four patients (7.84%) had inconclusive
results (Alencar et al., 2008).
2.2. HCV RNA extraction and synthesis of the complementary
DNA (cDNA)
HCV-RNA extraction was  carried out from 140 L of serum using
QIAamp® Viral RNA Kit (QIAGEN, Valencia, CA, USA), following the
manufacturer’s instructions. Synthesis of the complementary DNA
(cDNA) was  made immediately after RNA extraction. Reverse tran-
scriptase reaction was performed using Moloney Murine Leukemia
Virus Reverse Transcriptase (MMLV-RT) and random primers. The
ﬁnal volume of the reaction was  60 L with the following con-
centrations: 50 mM Tris–HCl (pH = 8.3), 75 mM KCl, 3 mM MgCl2,
10 mM  DTT, 0.5 mM  each dNTP (10 mM),  450 ng random primers,
30 units RNAse enzyme inhibitor (RNase OUTTM) and 300 units
MMLV-RT. Samples were submitted to the following temperature
cycles: 70 ◦C for 10 min, 25 ◦C for 15 min, 37 ◦C for 60 min  and 95 ◦C
for 15 min  in a thermocycler (Eppendorf Mastercycler®, Eppendorf,
Hamburg, Germany).
2.3. Polymerase chain reaction (PCR)
Polymerase chain reactions (PCR) were carried out in two stages,
ﬁrst and second PCR, to increase its sensitivity. A 380 bp frag-
ment covering the NS5B region was  ampliﬁed for genotyping
analysis using conditions previously described (Enomoto et al.,
1990; Sandres-Saune et al., 2003). Reactions were carried out in
a ﬁnal volume of 50 L. The cDNA (5 L) was  added to 20 mM
Tris–HCl (pH = 8.3), 50 mM KCl, 1.5 mM MgCl2, 0.2 mM each dNTP
(10 mM),  0.4 pmol/L  of each primer, and 2.5 units Platinum Taq
DNA polymerase. All the reagents used were from InvitrogenTM Life
Technologies, Carlsbad, CA, USA.
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Fig. 2. The maximum clade credibility (MCC) tree was  estimated by Bayesian analysis of 244 HCV NS5B sequences. The posterior probabilities of the key nodes are depicted
a d taxe
c this ﬁg
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obove  the respective nodes. The samples obtained from Pernambuco state (n = 63, re
orrespond to the other HCV subtypes. (For interpretation of references to color in 
.4. HCV NS5B sequencing
Ampliﬁed cDNA was puriﬁed using ChargeSwitch® PCR Clean-
p Kit. Sequencing was performed in an Applied Biosystems®
500 Genetic Analyzer (Life Technologies, Foster City, CA, USA)
sing dideoxynucleoside triphosphates (ddNTPs) containing ﬂu-
rescent markers (Big Dye® Terminator v3.1 Cycle Sequencings) were analyzed together other HCV strain from the Genbank. The collapsed clades
ure legend, the reader is referred to the web version of this article.)
Ready Reaction kit – Life Technology’s, Foster City, CA, USA).
The quality of each electropherogram was  evaluated using the
Phred-Phrap software (Ewing and Green, 1998; Ewing et al.,
1998) and consensus sequences were obtained by alignment of
both sequenced strands (sense and antisense) using CAP3 soft-
ware available at the web page Electropherogram quality analysis
(http://asparagin.cenargen.embrapa.br/phph/).
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.5. Phylogenetic analysis
The HCV sequences were genotyped by phylogenetic recon-
tructions using reference NS5B sequences from each HCV subtype
btained from GenBank (n = 224). The sequences were aligned
sing Muscle software (Edgar, 2004) and edited in the SE-AL
rogram (available at http://tree.bio.ed.ac.uk/software/seal/). The
arameters of the evolutionary model of DNA substitution were
stimated by MODELTEST v.3.7 (Posada and Crandall, 1998).
hylogenetic analyses were conducted using the Markov Chain
onte Carlo (MCMC) simulation implemented in BEAST v.1.5.3
Drummond and Rambaut, 2007) by both relaxed uncorrelated
ognormal and relaxed uncorrelated exponential molecular clock
sing (GTR+G+I) model of nucleotide substitution. Twenty million
enerations were run to obtain the convergence of parameters. The
aximum clade credibility (MCC) tree was obtained from sum-
arizing the substitution trees and then it was removed 10% of
urn-in using Tree Annotator v.1.5.3 (Drummond and Rambaut,
007). Phylogenetic trees were visualized and midpoint rooted in
igTree v1.2.2 (http://tree.bio.ed.ac.uk/software/ﬁgtree).
.6. Statistical analyses
Statistical analyses were performed using Minitab Software
.15. The 2 test for linear trend (  ˛ = 0.05) was used to examine the
istribution of HCV subtypes in patients according to age group,
ex, geographical origin, previous treatment and presence of HES.
esults were considered statistically signiﬁcant when p < 0.05.
. Results
We obtained 63 (74.1%) PCR positive samples that were suc-
essfully sequenced. To analyze the distribution of HCV genotypes
n this population, phylogenetic trees were reconstructed with the
btained NS5B region sequences. Subtype 1b was  the most fre-
uent in this population (42–66.7%), followed by 3a (16–25.4%),
a (4–6.3%) and 2b (1–1.6%) (Fig. 2). All sequences were deposed in
enBank (accession numbers: JQ323440–JQ323502).
When the capital city was compared with the other regions, we
ound the same distribution: 45 positive samples were from Recife
1b (30–66.7%), 3a (12–26.7%), 1a (2–4.4%) and 2b (1–2.2%)] and
8 positive samples were from other small towns [1b (12–66.7%),
a (4–22.2%) and 1a (2–11.1%)]. Also, among the 19 PCR positive
atients that presented hepatosplenic form of the schistosomiasis
HCV/HES) (ten from Recife and nine from the other small towns),
welve (63.2%) were infected with subtype 1b and seven (36.8%)
ith subtype 3a, respectively. Finally, the only one subtype 2b was
ound in a HCV/HIV patient.
Statistical analyses were carried out to analyze the distribution
f HCV subtypes in the different demographic and clinical variables.
tatically signiﬁcance was not found when genotypes distribution
as analyzed according to sex (p = 0.745), presence of HCV/HES
p = 0.130), origin (Recife vs. others) (p = 0.842) and previous antivi-
al treatment (treatment-naïve and previously treated patients –
on-responders) (p = 0.487).
. Discussion
In Brazil, the main risk factors of HCV infection are (i) indi-
iduals who received blood transfusions before 1993 and (ii)
njecting drug users under 30 years (Toledo et al., 2005; Silva
t al., 1995). A recently study shows that the overall result for
nti-HCV prevalence in all capital cities from Brazilian states was
.38% (95% CI 1.12–1.64%). Particularly, HCV prevalence from
tate capitals of the Northeast region ranged from 0.4 to 1.0% Research 169 (2012) 8– 12 11
(http://www.aids.gov.br/publicacao/2011/estudo de prevalencia
de base populacional das infeccoes pelos virus das hepatites b).
These results place this Brazilian region as a low HCV prevalence
area. Others studies were carried out to evaluate HCV in particular
groups from Pernambuco state: among hemodialysis and schisto-
somiasis patients, HCV frequency was  8.4% (Mello Lde et al., 2007)
and 11.9% (Silva et al., 2008), respectively.
In Latin America, genotype 1 is the most prevalent (Mendez-
Sanchez et al., 2010). Nonetheless, differences in distribution of
genotypes of HCV have been observed within our continent, par-
ticularly in the Caribbean region, where genotypes 2 and 4 have a
major frequency, differing from the rest of Latin America (Jimenez-
Mendez et al., 2010; Martial et al., 2004). In Brazil, Campiotto et al.,
2005 reported that genotype 1 was  the most frequently genotype.
Particularly, in the North region, genotype 1 was the most preva-
lent in Amazonas and Acre states (78.0% and 64.3%, respectively),
followed by genotype 3. In Pernambuco, genotype 1 was  the most
prevalent (60.7%), followed by genotypes 3 (36.9%) and 2 (2.4%).
Also, in HCV/HIV patients from this state, the most common HCV
subtypes were 1b (45%), 3 (33%) and 1a (22%) and the results of
multiple logistic regression conﬁrms the variable blood transfusion
was  a remaining risk factor for HCV (Carvalho et al., 2009). When
compare with other states from the Northeast region of Brazil,
for example, Piauí, it was observed a homogeneous distribution
between genotypes 1 (50.0%) and 3a (49.0%) (Veras et al., 2009).
In Rondônia state, located in the Northwestern region in Brazil, it
was  found 50% of presence of subtype 1b, followed by 1a (27.2%),
2b (13.6%) and 3a (9.0%) (Vieira et al., 2011).
Subtype 1b is mainly found among old people who have a pre-
vious history of blood transfusion and is related with a higher
rate of chronic active hepatitis or cirrhosis and low response to
treatment with Peg-interferon plus Ribavirin compared with geno-
types 2 and 3 (Pawlotsky, 2003; Mora et al., 2010). Furthermore,
molecular epidemiology studies have shown that HCV genotype 3,
subtype 3a (HCV-3a) is signiﬁcantly associated with transmission
through injecting drug use in industrialized countries (Pawlotsky
et al., 1995; Bourliere et al., 2002). HCV-3a apparently emerged
originally and diversiﬁed in Asia (potentially South- East Asia, and
the Indian subcontinent), where multiple other subtypes of HCV
genotype 3 have been described (Lole et al., 2003). Recently, it
was  reported that there was a signiﬁcant increase in cocaine con-
sumption among students in the State capitals of the Northeast of
Brazil (Salvador, Bahia; Recife, Pernambuco; and Fortaleza, Ceará)
(Duailibi et al., 2008). Also, it was  determined 6.9% of prevalence
rates of drug use among 4230 high school students from Pernam-
buco State (Carvalho et al., 2011). Since we  not have data about
injecting drug use in these patients, we  cannot perfom more infer-
ences about this, but probably this practice in the population may
be is associated with signiﬁcant prevalence of the subtype 3a found
in this state.
Schistosomiasis is a parasitic infection that also affects the liver
and is considered a public health problem in many different Brazil-
ian regions (SVS, 2005). It has been previously described that it
might alter the evolution of viral hepatitis (Aquino et al., 2000),
especially for hepatitis B. It has also been previously described that
this infection was  associated with a higher prevalence of anti-HCV
and it might be associated with a different distribution of HCV geno-
types, but the distribution of HCV genotypes was  not different from
the overall group.
5. ConclusionsIn conclusion, this study reports a high frequency of subtype 1b
and 3a among HCV patients from Pernambuco State. Our results
also shows that HCV infection in this region derives from different
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CV lineages that are circulating also around the world and not
o a particular strain that was associated to most infections in this
rea. More studies are needed to allow a better understanding of
he dynamics of the HCV epidemic in this state to development of
n effective prevention policy.
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